Goldman Sachs
CAMP icon

Goldman Sachs’s CAMP4 Therapeutics CAMP Stock Holding History

Goldman Sachs’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$346K Buy
78,345
+59,522
+316% +$283K ﹤0.01% 5816
2025
Q4 		$115K Buy
+18,823
New +$80.1K ﹤0.01% 6167
2025
Q3 		– Sell
-26,511
Closed -$38.4K – 6358
2025
Q2 		$38.4K Buy
26,511
+14,556
+122% +$29K ﹤0.01% 5940
2025
Q1 		$47.8K Sell
11,955
-5,535
-32% -$26.8K ﹤0.01% 5884
2024
Q4 		$91.3K Buy
+17,490
New +$144K ﹤0.01% 5778

Other funds holding CAMP

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs's CAMP Position: Q1 2026 in Review

Goldman Sachs increased its CAMP4 Therapeutics (CAMP) stake by 316% in Q1 2026, buying an estimated $283K and bringing the position to 78,345 shares worth $346K. The position accounts for ﹤0.01% of the portfolio, ranked #5816.

Goldman Sachs first reported a position in CAMP in Q4 2024 and has held it in 5 quarters since. 46 funds tracked by Wall St. Rank hold CAMP as of Q1 2026.

  • Goldman Sachs held 78,345 shares of CAMP4 Therapeutics worth $346K as of Q1 2026.
  • Goldman Sachs bought 59,522 CAMP4 Therapeutics shares in Q1 2026, an estimated $283K.
  • CAMP4 Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5816 holding.
  • Goldman Sachs first reported a position in CAMP4 Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • 46 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.